Abstract
The sensitivity of the dopaminergic hypothalamic pituitary system, as indicated by growth hormone (GH) release after apomorphine (0.5 mg SC), was studied in 11 chronic schizophrenic in-patients under long-term neuroleptic (NL) therapy and after 12 and 30 days' drug withdrawal. GH peak levels after a 12-day drug-free period were significantly elevated (13.1±12 ng/ml) as compared to NL therapy (4.6±6.1 ng/ml). Controls showed a significant higher mean peak GH response (13.6±10 ng/ml) compared to chronic schizophrenic patients under long-term NL therapy. The GH response of patients with symptoms of tardive dyskinesia (TD) did not differ significantly from that of patients without signs of TD.
The prolactin (PRL) serum levels under long-term NL treatment were within the normal range in male schizophrenics but decreased significantly after 12 days' drug withdrawal. The data presented indicate a reduced sensitivity of the hypothalamic-pituitary dopamine receptors under long-term NL therapy. The significant increase in GH response on day 12 probably corresponds to a readjustment from a mostly blunted GH response under NL therapy back to stimulated levels of normal controls. No supersensitivity of the pituitary dopamine recpetors could be detected.
This is a preview of subscription content, log in via an institution to check access.
References
Ackenheil M (1981) Biochemical effects of apomorphine: contribution to schizophrenia research. In: Corsini GU and Gessa GL (eds) Apomorphine and dopaminomimetics, vol II, Raven Press, New York, pp 215–255
Burt D, Creese J, Snyder S (1977) Antipsychotic drugs: Chronic treatment elevates dopamine receptor binding in brain. Science 196:326
Carlsson A (1975) Receptor mediated control of dopamine metabolism. In: Usdin E and Bunney WE (eds) Pre- and postsynaptic receptors. Marcel Dekker. New York
Christensen AV, Möller-Nielsen I (1979) Dopaminergic supersensitivity: Influence of dopamine agonists, cholinergics, anticholinergics, and drugs used for the treatment of tardive dyskinesia. Psychopharmacology 62:111–116
Cleghorn JM, Brown GM, Brown PJ, Kaplan RD, Dermer SW, Crimmon DJ, Mitton J (1983) Growth hormone responses to apomorphine HCL in schizophrenic patients on drug holidays and at relapse. Br J Psychiatry 142:482–488
Crow TJ (1980) Molecular pathology of schizophrenia: More than one disease process? Br Med J 280:66–68
Davis JM, Cole JO (1975) Antipsychotic drugs. In: Freedman AM, Kaplan HI, Sadock BJ (eds) Comprehensive textbook of psychiatry, vol 2 Williams Wilkins, Baltimore pp 1921–1941
De Rivera JL, Lal S, Ettigi P, Müller HF, Friesen HG (1976) Effect of acute and chronic neuroleptic therapy on serum prolactin levels in men and women of different age groups. Clin Endocrinol 5:273–282
Ettigi P, Nair NPV, Lal S, Cervantes P, Guyda H (1976) Effect of apomorphine on growth hormone and prolactin in schizophrenic patients, with or without oral dyskinesia, withdrawn from chronic neuroleptic therapy. J Neurol Neurosurg Psychiatr 39:870–876
Friend WC, Brown GM, Jawahir G, Lee T, Seeman P (1978) Effect of haloperidol and apomorphine treatment on dopamine receptorsin pituitary and striatum. Am J Psychiatry 135:839–841
Gerlach J (1979) Tardive dyskinesia. Dan Med Bull 26:209–245
Gianutsos G, Drawbaugh RB, Hynes MD et al. (1974) Behavioral evidence for dopaminergic supersensitivity after chronic haloperidol. Life Sci 14:887–898
Gruen PH, Sachar EJ, Langer G, Altmann N, Leifer M, Frantz A, Halpern FS (1978) Prolactin responses to neuroleptics in normal and schizophrenic subjects. Arch Gen Psychiatry 35:108–116
Heinrich K, Wegener I, Bender HJ (1968) Späte extrapyramidale Hyperkinesen bei neuroleptischer Langzeittherapie. Pharmakopsychiatr-Neuropsychopharmacol 1:169–195
Hwang P, Guyda H, Friesen HG (1971) A radioimmunoassay for human prolactin. Proc Natl Acad Sci USA 68:1902–1906
Keller HH, Bartholini G, Pletscher A (1973) Increase of MHPG in rat brain by neuroleptic drugs. Eur J Pharmacol 23:183–186
Klawans HL, Christopher GG, Stuart P (1980) Tardive dyskinesia: Review and update. Am J Psychiatry 137:900–908
Kolakowska T, Wiles DH, Gelder MG, McNelly AS (1976) Clinical significance of plasma chlorpromazine levels. Psychopharmacology 49:101–107
Lal S, Martin JB, De La Vega CE, Friesen HG (1975) Comparison of the effect of apomorphine and L-DOPA on serum growth hormone levels in normal man. Clin Endocrinol 4:277–285
Maany I, Frazer A, Mendels J (1975) apomorphine: Effect on growth hormone. J Clin Endocrinol Metab 40:162–163
Martres MP, Costenin J, Baudry M, Marcais H, Protais P, Schwartz JC (1978) Long-term changes in the sensitivity of pre-and postsynaptic dopamine receptors in mouse striatum evidenced by behavioral and biochemical studies. Brain Res 136:319–337
Meltzer HY, Stahl SM (1976) The dopamine hypothesis of schizophrenia: A review. Schizophrenia Bull 2:19–76
Meltzer HY, Goode DJ, Fang VS (1978a) The effects of psychotropic drugs on endocrine function. I Neuroleptics, precursors and agonists. In: Lipton MA, Mascio A, Killam KF (eds) Psychopharmacology: A Generation of progress. Press, N.Y. pp 509–530
Meltzer HY, Busch D, Fang VS (1981) Hormones, dopamine receptors and schizophrenia. Psychoneuroendocrinology, vol 6, no 1, pp 17–36
Muller P, Seeman P (1978) Dopaminergic supersensitivity after neuroleptics: Time course and specifity. Psychopharmacology 60:1–11
Naber D, Ackenheil M, Laakmann G, Fischer H, Werder K von (1980) Basal and stimulated levels of prolactin, TSH and LH in serum of chronic schizophrenic patients, long-term treated with neuroleptics. Pharmakopsychiat 13:325–330
Naber D, Müller F (1984) Effects of long-term neuroleptic treatment on serum levels of prolactin, TSH, LH and norepinephrine and on-adrenergic and dopaminergic receptor sensitivity. Relation to tardive dyskinesia. In: Shah NS, Donald AH (eds) Psychoneuroendocrine dysfunction. Plenum Publishing Corporation pp 599–612
Overall JE, Gorham DR (1976) Brief psychiatric rating scale. In: Guy W (ed) ECDEU Assessment manual for psychopathology, Rev. Ed. Rockville, pp 157–169
Pandey GN, Garver DL, Tamminga C, Ericksen S, Ali SJ, Davis JM (1977) Postsynaptic supersensitivity in schizophrenia. Am J Psychiatry 134:518–522
Rotrosen J, Angrist B, Gershon S, Paquin J, Branchey L, Oleshansky M, Halpern FS, Sachar EJ (1979) Neuroendocrine effects on apomorphine: Characterization of response patterns and application to schizophrenia research. Br J Psychiatry 135:444–456
Tamminga CA, Smith RC, Pandey G, Frohmann LA, Davis JM (1977) A neuroendocrine study of supersensitivity in tardive dyskinesia. Arch Gen Psychiatry 34:1199–1203
Valchar M, Metysova J, Chlebounova J, Dlabac A (1982) Induction of dopaminergic supersensitivity after a single dose of the neuroleptic isofloxythepin. Psychopharmacology 76:381–384
Webster DD (1968) Critical analysis of disability in Parkinson's disease. Mo Treatment 5:257–282
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Müller-Spahn, F., Ackenheil, M., Albus, M. et al. Neuroendocrine effects of apomorphine in chronic schizophrenic patients under long-term neuroleptic therapy and after drug withdrawal: Relations to psychopathology and tardive dyskinesia. Psychopharmacology 84, 436–440 (1984). https://doi.org/10.1007/BF00555228
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00555228